May is Skin Cancer Awareness Month

In recognition of May being Skin Cancer Awareness Month the Cancer Research UK Oxford Centre will be posting a series of blog posts highlighting the contribution of Oxford researchers to global efforts to tackle Melanoma.

Melanoma is the 5th most common cancer in the UK, and although it is more common in older people, it is relatively common in younger people. In 2015 about 16,000 people in the UK were diagnosed with melanoma, and within the last decade this number has increased by almost 50%. Over 2,500 of these people will develop advanced disease. Treatment of Advanced Melanoma has recently been transformed by introducing immunotherapies and targeted inhibitors in the treatment of patients who are not cured by surgery.

Oxford’s researchers have a broad range of scientific backgrounds and expertise, and are focused on trying to develop novel immunotherapies (such as innate immune stimulators and oncolytic viruses) to treat Melanoma. They are also interested in how the behaviour of melanoma cells can change under stress. Other scientists are working on better tests to predict who benefits from new treatments, like immunotherapy, and to identify who is likely to get side effects. One example of the type of projects Oxford researchers have been involved in is the early clinical development of the new drug IMCgp100, which has shown promise in treating Melanoma patients, whose cancer cannot be removed with surgery or has spread to other parts of the body.

Further efforts of the Oxford community are typified in the articles summarised below.
(Researcher spotlights will be listed here throughoyt May)

Prof Mark Middleton – Co-director of the Cancer research UK Oxford Centre & Head of the Department of Oncology.

The relationship between unexpected weight loss & cancer

New research will help GPs to identify the signs they should look for to swiftly diagnose cancer in people with unexpected weight loss

Researchers discover mutation that determines treatment efficiency

Weatherall Institute of Molecular Medicine researchers have recently discovered why a class of cancer drugs is beneficial only in a subset of patients

Mapping the T-cell landscape of pancreatic cancer

Through analysis of T-cell populations, researchers Drs Enas Abu-Shah & Shivan Sivakumar identify novel therapeutic opportunities in pancreatic cancer patients

Oxford to lead new programme of AI research to improve lung cancer screening

Science Minister Amanda Solloway today announced Oxford will lead a new national programme of AI research to improve lung cancer screening

New start-up Base Genomics launches

Base Genomics is based on Dr Chunxiao Song’s innovative TAPS technology, break-through Oxford-developed DNA methylation technology

Tackling oesophageal cancer early detection challenges through AI

Dr Sharib Ali specialises in the applications of AI to early oesophageal cancer detection

What is a clinical trial? - new video series

What expect at every stage of an early phase clinical trial, so patients can make the most informed decision.